IE
EWTX icon

Israel Englander’s Edgewise Therapeutics EWTX Stock Holding History

Israel Englander’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,000
Closed -$1.87M – 6083
2024
Q3 		$1.87M Buy
+70,000
New +$1.39M ﹤0.01% 3763

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Israel Englander's EWTX Position: Q2 2026 in Review

Israel Englander sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 342,867 shares — an estimated $10.8M sold.

Israel Englander first reported a position in EWTX in Q1 2021 and held it in 16 quarters. The position peaked at $26.3M in Q3 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Israel Englander reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 342,867 Edgewise Therapeutics shares in Q2 2026, an estimated $10.8M.
  • Israel Englander first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 16 quarters.
  • Israel Englander's Edgewise Therapeutics position peaked at $26.3M in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.